The next round of national harvest into the variety schedule out.

The latest news shows that the biological products, traditional Chinese medicine collection, blood products, vaccines, growth hormone and so on are not involved, Chinese medicine formula particles, Chinese medicine tablets and Chinese traditional medicine exclusive varieties are not considered.
of bio-drugs, traditional Chinese medicine collection, the latest news came yesterday, according to industry media news, July 15-16, the National Health Insurance Administration held a symposium on biological products (including insulin) and traditional Chinese medicine, experts at an investor conference to share the basic situation of the meeting.
the basic points are as follows: 1, the medical insurance bureau symposium is only to organize the relevant experts to conduct a preliminary discussion, to express relevant views.
the experts at the meeting have some controversy about the future biological products and the problems related to the collection of traditional Chinese medicine, especially on the basis of the evaluation of non-quality consistency, how to carry out the classification of quality level.
2, from the time process, this symposium is only the first expert discussion exchange, if the policy is smoothly advanced, as soon as early 2021 to come out of the first draft, and then further research.
the future of the country may still do some exploration, combined with the province's specific work arrangements, the entire volume of procurement to the implementation.
3. From the perspective of the participating categories, the early stage may choose the market for less controversial quality varieties to participate in the pilot, such as insulin and some biosimilar drugs.
from the category point of view, blood products, vaccines, growth hormone and so on are not very involved, Chinese medicine formula particles and Chinese medicine tablets are not too involved.
the first round of tape procurement from 2018 onwards, in 2019 4 plus 7 band purchase winning variety expansion, 2020 the third batch of tape procurement is about to start.
at the same time, some provinces began to explore the purchase of drug tape without consistency evaluation, this symposium, the selection of collected varieties from chemical generics to biopharmaceuticals and traditional Chinese medicine, the coverage of the continued expansion of the trend has been determined.
focus on insulin, do not consider the exclusive varieties of traditional Chinese medicine experts revealed that the symposium is still in the first stage, mainly invited some industry experts to talk about biological products, Chinese medicine two major categories of products, the exclusive varieties of Traditional Chinese medicine is not considered in the context.
it is worth noting that this time did not involve specific biological products and chinese medicine species, there is no specific rule-making, mainly some professional opinions and academic views, some experts are mainly in the absence of consistency evaluation on the basis of biological products and traditional Chinese medicine classification issues or quality level division.
in the case of insulin, future collection will involve the internal classification of insulin (second, third and its internal categories), as well as the classification of quality (e.g. whether there is a difference between domestic insulin and imported insulin, which is more controversial).
In addition to biological products, this is where the collection of traditional Chinese medicine is controversial - it is relatively difficult to measure quality because of its different processes and different raw materials.
on the selection of varieties, the scope of biological products mainly includes insulin and some biologically similar drugs, but does not include blood products and vaccines, because blood products related to raw materials, not suitable for the purchase of the amount of chinese medicine, but not involved in Chinese medicine formula particles and Chinese medicine tablets.
although the collection symposium did not confirm any varieties, but the total is traceable.
experts believe that in the future, priority will be given to non-controversial products - such as supply problems, quality issues or patent disputes - will not be taken into account, certainly the choice of recognized products to do.
local collection, there have been precedents to some extent, biological products with volume procurement in China has a precedent.
early 2020, Wuhan took the lead in the country to start the procurement of insulin band volume, and in May Qinghai Province's sample procurement list also includes human haemoglobin and other products.
Southwest Securities analysis, biological products in China's development time is relatively late than chemical and traditional Chinese medicine, some products of higher quality level, research and development difficult, the number of production enterprises relatively small, relatively moderate market competition;
but it's important to note that the reason for the volume purchase is to buy the value of health insurance - to pay for something worth buying, not to pay for biosimilars, which will encourage companies to do more sophisticated imitations or innovations, but not pay for them.
therefore, the future of bulk procurement of biological products will still be concentrated in public hospitals channel sales, sales of large and in the health insurance catalog of products - recombinant protein drugs such as insulin is the focus area of collection, the subsequent accelerated introduction of biosimilars may also enter the collection.
the purchase of traditional Chinese medicine exploration band purchase is not new, may Qinghai Province belt purchase directory includes blood plug pass, thrombosis, sputum heat clean and other Chinese medicine injections, to some extent, in the tide of medical insurance fees, Traditional Chinese medicine is not privileged.
in addition, in the past 5 years, the State Drug Administration announced the drug adverse reaction monitoring feedback, although the proportion of Chinese medicine injections and Chinese medicine in the overall adverse reactions is basically stable, but the basic proportion of Chinese medicine injections in the overall Chinese medicine is more than 50%, in the last 3 years there is a small increase, adverse reactions are not obvious.
Southwest Securities analysis that: in the hospital side sales is large, the efficacy is accurate, in the medical insurance catalog of oral Chinese medicine varieties into the collection catalog is more likely, and the main retail channels, non-medical insurance, partial consumption of traditional Chinese medicine into the possibility is lower, the early sales of more affected Chinese medicine injections into the catalog is less likely.
.